Topic: cannabinoid receptor 1

Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide. One of the hallmarks of PD is the alteration in the expression and function of NMDA receptor (NMDAR) and cannabinoid receptor 1 (CB1R). The presence of CB1R-NMDAR complexes has been described in neuronal primary cultures, where the activation of CB1R was suggested to counteract the detrimental NMDAR overactivation in an AD mice model. Thus, we aimed to explore the role of this receptor complex in PD. By using BRET assay, it was demonstrated that a-synuclein induces a reorganization of CB1R-NMDAR complex in

Synthetic cannabinoids as potent recreational drugs disrupt the endocannabinoid system in the brain, leading to severe mental and behavioral consequences. Cumyl-PINACA or SGT-24 is a synthetic agonist designed to bind cannabinoid receptor 1 (CB1) with very high affinity, yet the molecular mechanisms underlying its central toxic effects are poorly understood.In this study, we investigated the response of rat cortical neurons and astrocytes to SGT-24 at nanomolar concentrations (0.1 - 1000 nM). The effects of SGT-24 were dose- and time-dependent, as well as cell-specific. In neurons, 10 nM SGT-2